国立情報学研究所で電子化したコンテンツを使用している。

Cyclosporine is a commonly used immunosuppressive drug in dogs, but dosing is often empirical and based primarily on clinical response. Pharmacokinetic monitoring of blood drug concentrations can be performed, but target blood concentrations for various disease states in dogs are not well described. Pharmacodynamic assays measuring the effects of cyclosporine on target cells are being used to evaluate immunosuppressive effectiveness in humans, but have been minimally explored in veterinary medicine. This dissertation describes the development of pharmacodynamic assays for measuring the effects of cyclosporine on canine T cell cytokine production and surface antigen expression. Incubation with cyclosporine in vitro caused significant suppression of activated T cell production of interleukin-2 (IL-2), IL-4, interferon-gamma (IFN-gamma), CD25, and CD95 measured in peripheral blood mononuclear cells using flow cytometry. IL-2 and IFN-gamma were then evaluated using flow cytometry and quantitative reverse transcription polymerase chain reaction (qRT-PCR) in whole blood incubated with cyclosporine and dexamethasone in vitro. Cyclosporine caused concentration-dependent inhibition of both cytokines, and a greater degree of suppression was noted with qRT-PCR than flow cytometry. Dexamethasone caused concentration-dependent inhibition of IFN-gamma with both methods, but IL-2 reduction was only significant for qRT-PCR. Both methods were then used to evaluate IL-2 and IFN-gamma after administration of high dose oral cyclosporine to dogs. Both qRT-PCR and flow cytometry identified marked cytokine suppression after cyclosporine dosing, but qRT-PCR was uniformly suppressed across the 12-hour dosing interval, while flow cytometry results were significantly higher at trough blood drug concentrations than at peak blood concentrations and subsequent post-dosing time points. Both flow cytometry and qRT-PCR are valid methods for evaluation of T cell cytokine expression in dogs. Further study at lower drug doses is needed to correlate pharmacodynamic results with pharmacokinetic drug concentrations, and to confirm the best method for cytokine monitoring. Studies in clinic patients are also needed to determine the level of cytokine suppression associated with clinical effectiveness in different disease states. Pharmacodynamic evaluation of cyclosporine’s effects shows promise, and may allow for more individualized dosing of cyclosporine in dogs.

ABSTRACT MOLECULAR MECHANISMS AND GENE SIGNATURES INVOVLED IN CALCINEURIN INHIBITOR NEPHROTOXICITY IN KIDNEY ALLOGRAFT By Huong Le Diem Nguyen, M.S. A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science in Physiology at Virginia Commonwealth University. Virginia Commonwealth University, 2011. Major Director: Valeria Mas, Ph.D. Associate Professor, Department of Surgery and Pathology Director of Molecular Transplant Research Laboratory, Division of Transplant Calcineurin inhibitors (CNI), cyclosporin A and tacrolimus, are potent immunosuppressive agents but induce toxicities causing damages and graft dysfunction, and have been suggested to contribute to late-term loss of graft in kidney transplant recipients. Even though insights on mechanism of CNI nephrotoxicity have been uncovered, prevention and treatment of these toxicities remain a major challenge in the clinical administration of CNI due to low dose-toxicity correlation, difficulty in establishing a differential patho-histological diagnosis, and varying individual susceptibility. We hypothesize that CNI nephrotoxicity follows distinct disease pathways and is characterized by significant gene signatures that differentiate it from other conditions such as acute rejection and chronic allograft dysfunction. Moreover, we postulate that CNI-induced toxicity profiles contribute to the IF/TA signatures. Microarray analysis and gene annotation were done on the study database included of tissues diagnosed with CNI nephrotoxicity (n = 9), interstitial fibrosis/tubular atrophy (IF/TA, n=10), and normal allografts (NA, n = 8). All samples were histologically classified based on the revised Banff ‘07 criteria for renal allograft pathology. Top-scored biological networks in CNI tissues were related to metabolic disease, cellular development, renal necrosis, apoptosis cell-death, immunological disease, inflammatory disease, and many others. Canonical pathway analysis emphasized oxidative stress response mediated by NRF2 and various cell-death signaling pathways including 14-3-3 signaling pathway, p53 signaling pathway, and TGF-β signaling pathway. Profiling of differentially expressed genes was done based on their statistical significance and biological relevance to the unique pathology of CNI nephrotoxicity. Among these, three genes RGS1, CXCR4, and TGIF1 were further quantitatively evaluated using real time-PCR. Between CNI group and normal allograft, t-test results showed only RGS1 gene expression level was statistically significant. Between IF/TA group in normal allograft, both RGS1 and CXCR4 showed statistical significance. The calculated relative fold changes revealed an up-regulated pattern of RGS1 and CXCR4 expression in association with pathological groups (CNI and IF/TA). We did not, however, find any association between the expression of TGIF1 in either CNI group or IF/TA group.

Orientador: Luís Gustavo Modelli de Andrade / Resumo: Introdução: O Brasil é o maior serviço público de transplantes do mundo sendo a quase totalidade do seu financiamento custeado pelo sistema único de saúde. Os regimes de imunossupressão também são inteiramente financiados pelo Estado através do Componente Especializado de Assistência Farmacêutica, mas são pouco estudados sob a perspectiva econômica. O objetivo primário foi realizar uma análise de custo efetividade do regime de imunossupressão de tacrolimo com micofenolato comparado a tacrolimo associado a imTOR pelo período de um ano após o transplante renal. O objetivo secundário foi avaliar a não inferioridade destes dois regimes. Materiais e Métodos: Tratou-se de um estudo retrospectivo de transplantados renais realizados no Hospital das Clínicas de Botucatu, comparando protocolos de imunossupressão em 12 meses após o transplante. O primeiro esquema de imunossupressão foi o utilizado até outubro de 2015 e o segundo esquema adotado após mudança do protocolo do serviço. Foram feitas comparações entre os dois regimes de imunossupressão para avaliar a não inferioridade sendo definida como: o somatório dos eventos de rejeição aguda, descontinuidade, perda do enxerto e óbito ao fim de um ano. Para as análises de custo foi construído um modelo de análise de decisão no software TreeAge Pro 2009. As probabilidades de ocorrência dos eventos foram calculadas em cada grupo na amostra histórica. Foram conduzidas análises de sensibilidade visando obter uma simulação realista dos custos ... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: Introduction: Brazil is the largest public transplant service in the world, with almost all of its costs funded by the public health system. The immunosuppressive regimens are also fully funded by the state. These regimes were studied in terms of effectiveness, but they were poorly studied from an economic perspective. The primary objective was to conduct a cost-effectiveness analysis of the immunosuppressive regimen of tacrolimus with mycophenolate compared to tacrolimus associated with imTOR for a period of one year after kidney transplantation. The secondary objective was to assess the non-inferiority of these two regimens. Materials and Methods: This was a retrospective study of kidney transplants carried out at UNESP, Univ Estadual Paulista, comparing immunosuppressive protocols at 12 months after transplantation. The first immunosuppressive regimen was the one used until October 2015 and the second regimen adopted after changing the service protocol. Comparisons were made between the two immunosuppressive regimens to evaluate non-inferiority, defined as a composite end-point of biopsy proven acute rejection, graft loss, death, and adverse events leading to drug discontinuation. A decision analysis model was constructed with TreeAge Pro 2009 software to perform the cost analyzes. The probability of occurrence of clinical events was calculated for each group in the historical sample. Sensitivity analyzes were conducted in order to obtain a realistic simulation of the fina... (Complete abstract click electronic access below) / Mestre

Tacrolimus (TAC) é um fármaco imunossupressor muito utilizado na prevenção de rejeição aguda após o transplante de órgãos. Essa droga apresenta um índice terapêutico muito baixo e grande variabilidade intra e interindividual, sendo necessário programas de monitorização terapêutica para se otimizar a eficácia e limitar a toxicidade. O TAC é um fármaco substrato do CYP3A5 e transportado pela proteína de efluxo PGP e acredita-se que o polimorfismos genéticos (SNPs) destas proteínas estejam relacionados a alta variabilidade farmacocinética desta droga. Neste estudo, investigamos a influência dos polimorfismos destas proteínas sobre alguns parâmetros farmacocinéticos do TAC e também, na incidência de lesões renais e rejeição em receptores de transplante renal. Pacientes recebendo TAC a no mínimo 12 meses (n=108) foram genotipados (PCR real time) para os polimorfismos do CYP3A5*3 (rs776746) e do gene ABCB1 1236C>T (rs1128503), 2677G>T/A (rs2032582) e 3435C>T (rs1045642). Dados da concentração plasmática de vale (Co; ng/mL), dose diária normalizada (mg/dia por Kg do paciente) e a concentração plasmática do fármaco normalizada pela dose ingerida (Co/dose, ng/mL por mg/dia por kg do paciente) de TAC foram obtidos dos prontuários médicos ao longo de três anos após o transplante renal. O desfecho clínico foi analisado avaliando-se a curva de sobrevida o enxerto, a função renal obtida pelo clearance de creatinina (Equação de Cockroft-Gault), e desenvolvimento de lesões renais e rejeição aguda e crônica com diagnósticos estabelecidos mediante suspeita clínica e confirmados pela avaliação das biópsias quanto a presença de necrose tubular aguda (NTA) e nefropatia crônica do enxerto (NFC) de acordo com a classificação de BANFF 07. Os haplótipos do gene ABCB1 foram inferidos estatisticamente utilizando o software PHASE (version 2.1). Diferenças foram consideradas significativas quando p<0,05. Não observamos desvios em relação ao esperado pelo equilíbrio de Hardy-Weinberg em nossa população para nenhum dos genes estudados. Frequências alélicas destes polimorfismos (6986G 74%; 1236C 60%; 3435C 59% and 2677G 64%) e haplótipos (49% 2677G-3435C-1236C e 31% 2677T-3435T-1236T) foram consistentes com outros estudos realizados na população brasileira. Indivíduos portadores de ao menos um alelo *1 do gene CYP3A5 necessitavam de maiores doses de TAC para obter níveis plasmáticos semelhantes aos dos indivíduos homozigotos para o alelo *3 (0,09 ± 0,03 vs. 0,06 ± 0,03; mg/dia/kg; p<0,001). Ao final do primeiro ano de transplante pacientes CYP*3/*3 apresentavam praticamente o dobro da razão Co/dose quando comparados com os pacientes CYP*1/*1 (144,60 ± 67,29 vs. 70,44 ± 56,05 ng*mL-1 /mg*kg- 1 /dia; p<0,001). Observou-se semelhante em relação quando indivíduos portadores dos alelos e haplótipo variante da PGP foram avaliados. Não encontramos associações significativas entre os genótipos e a sobrevida do enxerto ou clearance de creatinina. No entanto, observamos que os pacientes portadores do haplótipo GCC apresentaram maior incidência de desenvolvimento de NFC. Este estudo confirma o efeito dos polimorfismos do CYP3A5 e, em menor grau da PGP na farmacocinética do TAC. No entanto, não encontramos associações entre esses polimorfismos e desfechos clínicos significantes, sugerindo que a genotipagem para o CYP3A5 ou ABCB1 ainda não deva ser incorporada na prática clínica como uma ferramenta para o manejo de transplante renal. / Tacrolimus (TAC) is widely used to prevent acute rejection following solid-organ transplantation. This drug is characterized by a narrow therapeutic index and drug monitoring programs are required both to optimize efficacy and to limit toxicity. TAC is known to be substrate of cytochrome P450 (CYP) 3A5 and P-glycoprotein (PGP/ABCB) and its been suggested that genetic polymorphisms (SNPs) of these proteins are highly associated with variations in TAC pharmacokinetics. We investigated the influence of polymorphisms of CYP3A5 and ABCB1 gene on the pharmacokinetic parameters (PK) of TAC and on the incidence of kidney injuries and allograft rejection (AR) in renal transplant recipients. Patients receiving TAC for at least 12 months (n=108) were genotyped (real-time PCR) for CYP3A5*3 (rs776746) and for ABCB1 1236C>T (rs1128503), 2677G>T/A (rs2032582) and 3435C>T (rs1045642) polymorphisms. TAC predose concentration (Co; ng/mL), TAC daily dose (mg/day per kg body weight) and dose-normalized predose concentrations (Co/dose; ng/mL per mg/day per kg body weight) were retrieved from medical records up to 03 years after transplantation. Clinical outcomes were analyzed evaluating renal function in terms of creatinine clearance ( Cockroft-Gault equation) and allograft survival. Kidney injuries and AR diagnostics were established by clinical suspicion and in presence of histological findings in renal biopsies according to the 2007 Banff classification. ABCB1 gene haplotypes were statistically inferred using PHASE software (version 2.1). No deviation from Hardy-Weinberg equilibrium was observed in our study population for the polymorphic loci examined in CYP3A5 and ABCB1. Allelic frequencies of these polymorphisms (6986G 74%; 1236C 60%; 3435C 60% and 2677G 65%) and haplotypes (49% 2677G-3435C-1236C and 30% 2677T- 3435T-1236T) were consistent with other studies in the Brazilian population. Individuals carrying at least one CYP3A5*1 allele required higher TAC dose to achieve similar TAC blood levels as the homozygous individuals for the *3 allele (0.09 ± 0.03 vs.0.06 ± 0.03, mg/day per kg body weight, p<0.001). The presence of the CYP3A5*1 allele was also associated with lower TAC Co/dose compared to CYP*3 homozygous (84.9 ± 43.2 vs. 144.6 ± 66.7 ng/mL per mg/day per kg body weight, p<0.001). Regarding ABCB1 polymorphisms, individuals homozygous for the variant allele of each individual SNP and for the haplotype (TTT) showed higher Co/dose ratio. No associations were found between SNPs or haplotypes and allograft survival or creatinine clearance. We did find, though, that patients carrying GCC haplotype had a higher incidence of chronic rejection. Our findings confirm the effect of CYP3A5 and, less pronounced of ABCB1 polymorphisms, on the TAC pharmacokinetic. On the other hand, we did not find any association between these polymorphisms and relevant clinical outcomes, suggesting that CYP3A5 and ABCB1 genotyping must not be incorporated as a useful clinical tool on the management of kidney transplantation.

Tacrolimus (TAC) é um fármaco imunossupressor muito utilizado na prevenção de rejeição aguda após o transplante de órgãos. Essa droga apresenta um índice terapêutico muito baixo e grande variabilidade intra e interindividual, sendo necessário programas de monitorização terapêutica para se otimizar a eficácia e limitar a toxicidade. O TAC é um fármaco substrato do CYP3A5 e transportado pela proteína de efluxo PGP e acredita-se que o polimorfismos genéticos (SNPs) destas proteínas estejam relacionados a alta variabilidade farmacocinética desta droga. Neste estudo, investigamos a influência dos polimorfismos destas proteínas sobre alguns parâmetros farmacocinéticos do TAC e também, na incidência de lesões renais e rejeição em receptores de transplante renal. Pacientes recebendo TAC a no mínimo 12 meses (n=108) foram genotipados (PCR real time) para os polimorfismos do CYP3A5*3 (rs776746) e do gene ABCB1 1236C>T (rs1128503), 2677G>T/A (rs2032582) e 3435C>T (rs1045642). Dados da concentração plasmática de vale (Co; ng/mL), dose diária normalizada (mg/dia por Kg do paciente) e a concentração plasmática do fármaco normalizada pela dose ingerida (Co/dose, ng/mL por mg/dia por kg do paciente) de TAC foram obtidos dos prontuários médicos ao longo de três anos após o transplante renal. O desfecho clínico foi analisado avaliando-se a curva de sobrevida o enxerto, a função renal obtida pelo clearance de creatinina (Equação de Cockroft-Gault), e desenvolvimento de lesões renais e rejeição aguda e crônica com diagnósticos estabelecidos mediante suspeita clínica e confirmados pela avaliação das biópsias quanto a presença de necrose tubular aguda (NTA) e nefropatia crônica do enxerto (NFC) de acordo com a classificação de BANFF 07. Os haplótipos do gene ABCB1 foram inferidos estatisticamente utilizando o software PHASE (version 2.1). Diferenças foram consideradas significativas quando p<0,05. Não observamos desvios em relação ao esperado pelo equilíbrio de Hardy-Weinberg em nossa população para nenhum dos genes estudados. Frequências alélicas destes polimorfismos (6986G 74%; 1236C 60%; 3435C 59% and 2677G 64%) e haplótipos (49% 2677G-3435C-1236C e 31% 2677T-3435T-1236T) foram consistentes com outros estudos realizados na população brasileira. Indivíduos portadores de ao menos um alelo *1 do gene CYP3A5 necessitavam de maiores doses de TAC para obter níveis plasmáticos semelhantes aos dos indivíduos homozigotos para o alelo *3 (0,09 ± 0,03 vs. 0,06 ± 0,03; mg/dia/kg; p<0,001). Ao final do primeiro ano de transplante pacientes CYP*3/*3 apresentavam praticamente o dobro da razão Co/dose quando comparados com os pacientes CYP*1/*1 (144,60 ± 67,29 vs. 70,44 ± 56,05 ng*mL-1 /mg*kg- 1 /dia; p<0,001). Observou-se semelhante em relação quando indivíduos portadores dos alelos e haplótipo variante da PGP foram avaliados. Não encontramos associações significativas entre os genótipos e a sobrevida do enxerto ou clearance de creatinina. No entanto, observamos que os pacientes portadores do haplótipo GCC apresentaram maior incidência de desenvolvimento de NFC. Este estudo confirma o efeito dos polimorfismos do CYP3A5 e, em menor grau da PGP na farmacocinética do TAC. No entanto, não encontramos associações entre esses polimorfismos e desfechos clínicos significantes, sugerindo que a genotipagem para o CYP3A5 ou ABCB1 ainda não deva ser incorporada na prática clínica como uma ferramenta para o manejo de transplante renal. / Tacrolimus (TAC) is widely used to prevent acute rejection following solid-organ transplantation. This drug is characterized by a narrow therapeutic index and drug monitoring programs are required both to optimize efficacy and to limit toxicity. TAC is known to be substrate of cytochrome P450 (CYP) 3A5 and P-glycoprotein (PGP/ABCB) and its been suggested that genetic polymorphisms (SNPs) of these proteins are highly associated with variations in TAC pharmacokinetics. We investigated the influence of polymorphisms of CYP3A5 and ABCB1 gene on the pharmacokinetic parameters (PK) of TAC and on the incidence of kidney injuries and allograft rejection (AR) in renal transplant recipients. Patients receiving TAC for at least 12 months (n=108) were genotyped (real-time PCR) for CYP3A5*3 (rs776746) and for ABCB1 1236C>T (rs1128503), 2677G>T/A (rs2032582) and 3435C>T (rs1045642) polymorphisms. TAC predose concentration (Co; ng/mL), TAC daily dose (mg/day per kg body weight) and dose-normalized predose concentrations (Co/dose; ng/mL per mg/day per kg body weight) were retrieved from medical records up to 03 years after transplantation. Clinical outcomes were analyzed evaluating renal function in terms of creatinine clearance ( Cockroft-Gault equation) and allograft survival. Kidney injuries and AR diagnostics were established by clinical suspicion and in presence of histological findings in renal biopsies according to the 2007 Banff classification. ABCB1 gene haplotypes were statistically inferred using PHASE software (version 2.1). No deviation from Hardy-Weinberg equilibrium was observed in our study population for the polymorphic loci examined in CYP3A5 and ABCB1. Allelic frequencies of these polymorphisms (6986G 74%; 1236C 60%; 3435C 60% and 2677G 65%) and haplotypes (49% 2677G-3435C-1236C and 30% 2677T- 3435T-1236T) were consistent with other studies in the Brazilian population. Individuals carrying at least one CYP3A5*1 allele required higher TAC dose to achieve similar TAC blood levels as the homozygous individuals for the *3 allele (0.09 ± 0.03 vs.0.06 ± 0.03, mg/day per kg body weight, p<0.001). The presence of the CYP3A5*1 allele was also associated with lower TAC Co/dose compared to CYP*3 homozygous (84.9 ± 43.2 vs. 144.6 ± 66.7 ng/mL per mg/day per kg body weight, p<0.001). Regarding ABCB1 polymorphisms, individuals homozygous for the variant allele of each individual SNP and for the haplotype (TTT) showed higher Co/dose ratio. No associations were found between SNPs or haplotypes and allograft survival or creatinine clearance. We did find, though, that patients carrying GCC haplotype had a higher incidence of chronic rejection. Our findings confirm the effect of CYP3A5 and, less pronounced of ABCB1 polymorphisms, on the TAC pharmacokinetic. On the other hand, we did not find any association between these polymorphisms and relevant clinical outcomes, suggesting that CYP3A5 and ABCB1 genotyping must not be incorporated as a useful clinical tool on the management of kidney transplantation.

In dieser Dissertation versuche ich, die zentralen Nitrogen-heterocyclischen Kerne, die Seitenketten und deren Position zu variieren. Als synthetische Strategie wurden Palladium-katalysierte Kupplungsreaktionen verwendet, um Seitenketten und Aryl-Substituenten einzuführen. Halogensubstituierte Diarylheterocyclen sind wichtige Intermediate in der Synthese der allgemeine Strukture. Die Einführung der gewünschten Seitenketten durch Carbon-Carbon und Carbon-Nitrogen-Bindungsknüpfung wurde durch Sonogashira-Kupplung, Heck-Kupplung und Buchwald-Hartwig-Aminierung erzielt. Mit der Sonogashira-Reaktion kann eine funktionalisierte Alkynylgruppe in die heterocyclischen Kerne effektiv und bequem eingeführt werden. Eine anschliessende katalytische Hydrierung der Alkynylgruppe führt zu funktionalisierten Alkyl substituierten Diarylheterocyclen. In der vorliegenden Arbeit wurden mehr als 180 Substanzen synthetisiert. Unter ihnen sind ungefähr 130 neue Substanzen. 86 von ihnen passen in die allgemeine Strukture. / In the present thesis, I tried to vary the central nitrogen-heterocyclic cores, the functionalised side chains and its position of attachment. As a synthetic strategy, palladium-catalyzed coupling reactions were used to introduce side chains and aryl substituents into the central heterocycle. In this way the utility of such reactions to heterocyclic systems, which were neglected so far, could be figured out. Halogen substituted diaryl heterocycles are important intermediates in the synthesis of general structures. The introduction of the desired side chains by Carbon-Carbon bond formation reactions was achieved by Sonogashira coupling and Heck coupling. Buchwald-Hartwig amination and nucleophilic substitution were used to establish side chains which are connected to the core heterocycle by heteroatom-Carbon bonds. Sonogashira reaction turned out to be the most effective and convenient method to introduce functionalized alkynyl group into the heterocyclic cores. In the present work, more than 180 compounds were synthesized. Among them, about 130 compounds are new products. 86 of them fit into the general structure.